Ocata Therapeutics Inc. (OCAT) Stock Analysis
DELISTED 2016
What happened to Ocata Therapeutics Inc. (OCAT) stock?
Ocata Therapeutics Inc. (OCAT) no longer trades on public markets. It was delisted in February 2016. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ocata Therapeutics Inc. (OCAT) trades at $8.47. Ocata Therapeutics Inc. was a biopharmaceutical company focused on developing regenerative medicine therapies for eye diseases. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for OCAT: OCAT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OCAT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Ocata Therapeutics Inc. (OCAT) Healthcare & Pipeline Overview
Ocata Therapeutics Inc., though no longer operating independently, focused on pioneering stem cell-based therapies for ocular diseases, particularly age-related macular degeneration. Its innovative approach aimed to regenerate retinal tissue, differentiating it within the competitive biotechnology landscape focused on vision loss.
What Is the Investment Thesis for OCAT?
Ocata Therapeutics Inc. presented a compelling investment thesis based on its pioneering work in stem cell-based therapies for ocular diseases. The company's focus on age-related macular degeneration (AMD), a significant and growing market, offered substantial potential. The gross margin of 60.5% indicated strong potential profitability if the company could bring a product to market. However, the negative P/E ratio of -9.25 and a profit margin of -22010.4% highlighted the significant financial risks associated with the company's high research and development costs and lack of revenue-generating products. The beta of 0.69 suggested lower volatility compared to the overall market. A key value driver was the potential for MA09-hRPE to become the first approved treatment for dry AMD. Upcoming catalysts included the advancement of clinical trials and potential partnerships. Potential risks included clinical trial failures, regulatory hurdles, and competition from other companies developing AMD therapies.
Based on FMP financials and quantitative analysis
OCAT Key Highlights
Gross margin of 60.5% suggests strong potential profitability upon successful product commercialization.
- Beta of 0.69 indicates lower volatility compared to the broader market.
- Focus on age-related macular degeneration (AMD) targets a large and growing market.
- MA09-hRPE represented a potential first-in-class treatment for dry AMD.
- P/E ratio of -9.25 reflects the company's lack of profitability due to high R&D expenses.
Who Are OCAT's Competitors?
OCAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCAT's Key Strengths?
Pioneering stem cell technology for retinal diseases.
- Potential first-in-class treatment for dry AMD.
- Experienced management team.
- Strong intellectual property portfolio.
What Are OCAT's Weaknesses?
High research and development costs.
- Lack of revenue-generating products.
- Dependence on clinical trial success.
- Regulatory hurdles for cell-based therapies.
What Could Drive OCAT Stock Higher?
Clinical trial results for MA09-hRPE in dry AMD.
- Potential partnerships with pharmaceutical companies.
- Regulatory approval of MA09-hRPE.
- Development of next-generation cell therapies.
What Are the Key Risks for OCAT?
Clinical trial failures.
- Competition from other AMD therapies.
- Regulatory delays or rejection.
- High research and development costs.
- Ethical concerns regarding stem cell research.
What Are the Growth Opportunities for OCAT?
- Expansion into other retinal diseases: Ocata could leverage its stem cell technology platform to develop therapies for other retinal diseases beyond AMD, such as Stargardt's disease and retinitis pigmentosa. These diseases represent significant unmet needs and could expand the company's market opportunity.
- Partnerships and collaborations: Ocata could pursue partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships could provide access to funding, expertise, and established distribution networks. Strategic collaborations could also help to expand the company's technology platform and pipeline.
- Advancement of MA09-hRPE: Successful completion of clinical trials and regulatory approval of MA09-hRPE for dry AMD would be a major growth driver. This would establish Ocata as a leader in the treatment of AMD and generate significant revenue. The dry AMD market is estimated to be worth billions of dollars annually.
- Development of next-generation cell therapies: Ocata could invest in the development of next-generation cell therapies with improved efficacy and safety profiles. This could involve optimizing the cell manufacturing process, enhancing cell survival and integration, or developing new cell delivery methods. Innovation in cell therapy technology could provide a competitive advantage and drive long-term growth.
- Geographic expansion: Ocata could expand its operations into new geographic markets, such as Europe and Asia. These markets have a growing aging population and increasing demand for advanced therapies for eye diseases. Geographic expansion would require establishing local partnerships and navigating regulatory requirements, but could significantly increase the company's revenue potential.
What Are OCAT's Competitive Advantages?
- Proprietary stem cell technology platform.
- Intellectual property protection for its cell therapies.
- Clinical data supporting the safety and efficacy of its products.
- Expertise in cell therapy manufacturing and development.
What Does OCAT Do?
Ocata Therapeutics Inc. was a biopharmaceutical company dedicated to the development of innovative regenerative medicine therapies for diseases of the eye. The company's core technology revolved around the use of human embryonic stem cells (hESCs) to generate retinal pigment epithelium (RPE) cells, which are critical for the health and function of the retina. Ocata believed that these RPE cells could be transplanted into patients with retinal diseases, potentially restoring vision. Founded with the vision of addressing unmet needs in the treatment of ocular disorders, Ocata focused primarily on age-related macular degeneration (AMD), a leading cause of vision loss in the elderly. Its lead product candidate, MA09-hRPE, was an RPE cell therapy designed to treat the dry form of AMD, which currently has no approved treatments. The company also explored the potential of its technology in other retinal diseases, such as Stargardt's disease. Ocata's research and development efforts involved significant investment in cell therapy manufacturing and clinical trials. The company conducted multiple clinical studies to evaluate the safety and efficacy of its RPE cell therapy. While Ocata Therapeutics Inc. is no longer operating independently, its work contributed to the advancement of regenerative medicine in ophthalmology.
What Products and Services Does OCAT Offer?
- Developed regenerative medicine therapies for eye diseases.
- Focused on using human embryonic stem cells (hESCs) to generate retinal pigment epithelium (RPE) cells.
- Aimed to treat age-related macular degeneration (AMD) with RPE cell therapy.
- Conducted clinical trials to evaluate the safety and efficacy of its RPE cell therapy.
- Explored the potential of its technology in other retinal diseases, such as Stargardt's disease.
- Pioneered stem cell-based approaches to restore vision in patients with retinal disorders.
How Does OCAT Make Money?
- Focused on research and development of cell-based therapies.
- Generated revenue through potential licensing agreements and partnerships.
- Sought to commercialize its therapies through direct sales or partnerships upon regulatory approval.
What Industry Does OCAT Operate In?
Ocata Therapeutics Inc. operated within the biotechnology industry, specifically targeting the ophthalmology market. This market is characterized by significant unmet needs, particularly in the treatment of age-related macular degeneration (AMD) and other retinal diseases. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms developing novel therapies, including gene therapies and cell therapies. The industry is driven by an aging population and increasing prevalence of vision-related disorders. Ocata's focus on stem cell-based therapies positioned it as an innovator in the regenerative medicine space, but also exposed it to the challenges of developing and commercializing complex cell-based products.
Who Are OCAT's Key Customers?
- Patients with age-related macular degeneration (AMD).
- Patients with Stargardt's disease.
- Ophthalmologists and retinal specialists.
- Healthcare providers and hospitals.
Company Profile
Ocata Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. OCAT has traded publicly since 2014.
Key Financial Metrics
Return on equity for Ocata Therapeutics Inc. stands at 275.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.84 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -10.8%, the inverse of the P/E and a quick read on earnings relative to price.
OCAT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that key stakeholders believe in its potential.
- Social sentiment has shifted positively, with discussions highlighting the company's innovative therapies and their potential impact on the market.
- Recent announcements regarding partnerships have generated excitement, fostering a sense of optimism among investors and the community.
- The overall biotech sector has seen increased interest, which may benefit Ocata as investors look for promising candidates in the space.
Bear Case
- Concerns linger about the competitive landscape, with emerging therapies potentially overshadowing Ocata's offerings.
- Recent negative sentiment in online communities suggests some investors are wary of the company's ability to deliver on its promises.
- Regulatory hurdles remain a significant concern, as any delays could impact the company's timelines and investor confidence.
- Market perception has been cautious, with some analysts questioning the sustainability of the company's recent momentum.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OCAT Latest News
No recent news available for OCAT.
What Investors Ask About Ocata Therapeutics Inc. (OCAT) — Healthcare
What happened to Ocata Therapeutics Inc. (OCAT) stock?
Ocata Therapeutics Inc. (OCAT) no longer trades on public markets. It was delisted in February 2016. The figures below are historical and are not a current quote.
Can I still buy OCAT shares?
No. OCAT stopped trading on public markets in February 2016, so the shares are not available through a broker. Anything you see quoted for OCAT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OCAT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Ocata Therapeutics Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Ocata Therapeutics Inc. do?
Ocata Therapeutics Inc. was a biopharmaceutical company that focused on developing regenerative medicine therapies for eye diseases. Their primary focus was on utilizing human embryonic stem cells to create retinal pigment epithelium (RPE) cells. These cells were intended to be transplanted into patients suffering from conditions like age-related macular degeneration (AMD) to regenerate damaged retinal tissue and potentially restore vision.
What are the main risks for OCAT?
The main risks for Ocata Therapeutics Inc. included the inherent challenges of developing and commercializing cell-based therapies. Clinical trial failures represented a significant risk, as the efficacy and safety of MA09-hRPE needed to be demonstrated in rigorous studies. Regulatory hurdles and potential delays in obtaining approval from regulatory agencies also posed a risk.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on historical data and may not reflect the current status of the company.
- AI analysis is pending for OCAT.